A new batch of data on Monday showed how immunotherapy, a new kind of cancer treatment that harnesses the body's immune system, works in lung cancer patients.
The data looked at how combinations of two rival immunotherapy drugs — made by Merck and Bristol-Myers Squibb — worked in treating a common form of lung cancer compared to traditional chemotherapy. While the trials looked at two different combinations — Merck with chemotherapy and BMS with another immunotherapy — the markets picked Merck as the winner, finishing the day up 2.6%.
Its late-stage trial, published in the New England Journal of Medicine, found that its immunotherapy drug in combination with another managed to keep lung cancers that had a certain number of mutations from getting worse for a longer period than those treated with chemotherapy.
Merck, on the other hand, showed that its drug Keytruda in combination with chemotherapy cut the risk of death in lung cancer patients in half. That was the case for all patients with advanced or metastatic nonsquamous non-small-cell lung cancer.
Bernstein analyst Tim Anderson said that the results Monday confirm Merck "will remain in the driver's seat." Even so, BMS is optimistic about its approach to immunotherapy-only combinations that treat a more specific patient population.
"Today is an important day from a scientific standpoint, from a medical standpoint, and also from a patient standpoint, that there are multiple options for patients, or more than we had in the past," Dr. Fouad Namouni, oncology development head at BMS, told Business Insider Monday afternoon.
BMS's trial looked at how the combination of its immunotherapy drugs, Opdivo and Yervoy, compared with chemotherapy in a group of people with lung cancer. It was the only company coming out with a treatment based strictly on immunotherapy.
Source : https://www.businessinsider.com/bristol-myers-squibb-immunotherapy-combination-data-2018-4